Her-2阳性乳腺癌新辅助治疗的研究进展

Research progress of neoadjuvant therapy for HER-2 positive breast cancer

人表皮生长因子受体-2(Her-2)是目前已知的一种重要的原癌基因。目前临床中使用靶向作用于Her-2靶点的药物可有效抑制信号通路的激活,实现对Her-2表达的调控,抑制细胞的恶性转化,具有较高的临床应用价值。近年来,Her-2阳性乳腺癌新辅助治疗的相关研究取得了大量积极进展,有助于提高临床应用效率。因此,本文对Her-2阳性乳腺癌新辅助治疗的研究进展进行综述。

Human epidermal growth factor receptor-2(HER-2)is an important proto oncogene known at present.At present,the use of drugs targeting HER-2 targets in clinic can effectively inhibit the activation of signal pathway,regulate HER-2 expression and inhibit the malignant transformation of cells,which has higher clinical application value.In recent years,the related research on neoadjuvant therapy for HER-2 positive breast cancer has made a lot of positive progress,which helps to improve the efficiency of clinical application.Therefore,this article reviews the research progress of neoadjuvant therapy for HER-2 positive breast cancer.